▴ Lubiprostone (Amitiza™) is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in increased fluid secretion.
▴ In two pivotal, randomised, double-blind, multicentre phase III studies in patients with chronic idiopathic constipation, the frequency of spontaneous bowel movements (SBMs) was significantly greater in patients receiving lubiprostone 24µg twice daily than in those receiving placebo at each weekly timepoint throughout both 4-week studies (p < 0.05).
▴ At week 1 in one pivotal trial, the mean frequency of SBMs in the lubiprostone group was 5.9 per week compared with 4.0 per week in the placebo group (p < 0.0001) [baseline SBMs 1.3 and 1.5 per week].
▴ Significantly greater improvements occurred with lubiprostone than placebo in the degree of straining, stool consistency and constipation severity (where reported) in both pivotal studies (p < 0.05 for all comparisons at all timepoints).
▴ Lubiprostone was generally well tolerated in clinical trials with no reports of treatment-related serious adverse events in pivotal trials. Nausea was the most common adverse event, occurring in up to 31% of patients receiving lubiprostone.
KeywordsChloride Channel Intestinal Fluid Pivotal Trial Stool Consistency Cystic Fibrosis Transmembrane Regulator
- 3.Sucampo Pharmaceuticals Inc. Amitiza (lubiprostone) prescribing information (revised March 2006) [online]. Available from URL: http://www.amitiza.com/resources/pi.pdf [Accessed 2006 Apr 10]
- 5.Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels [abstract no. M1109]. Gastroenterology 2004; 126 (4 Suppl. 2): A298Google Scholar
- 7.Ueno R, Perentesis GP, Engelke KJ, et al. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator, after a single oral dose in multiple animal species [abstract no. 76; published erratum regarding change in authorship appears in Neurogastroenterol Motil 18 (5): 403]. Neurogastroenterol Motil 2005; 17(4): 625Google Scholar
- 8.Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (C1C-2) activator for the treatment of constipation: safety and primary efficacy [abstract no. 896]. Am J Gastroenterol 2005 Sep; 100 Suppl. 9: s328–9Google Scholar
- 10.Johanson JF, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (C1C-2) activator for the treatment of constipation: data from a 4-week phase III study [abstract no. 884]. Am J Gastroenterol 2005 Sep; 100 Suppl. 9: s324–5Google Scholar
- 11.Johanson JF, Gargano MA, Holland PC, et al. Phase III patient assessments of the effects of lubiprostone, a chloride channel-2 (ClC-2) activator, for the treatment of constipation [abstract no. 899]. Am J Gastroenterol 2005 Sep; 100 Suppl. 9: s329–30Google Scholar
- 12.Johanson JF, Gargano MA, Holland PC, et al. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation [abstract no. 903]. Am J Gastroenterol 2005 Sep; 100 Suppl. 9: s331Google Scholar
- 13.Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [abstract no. 749]. Gastroenterology 2004 Apr; 126 (4 Suppl. 2): A100Google Scholar
- 14.Johanson JF, Gargano MA, Patchen ML, et al. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation [abstract no. M1511]. Gastroenterology 2002 Apr; 122 Suppl. 1: A3150Google Scholar